NEW YORK (GenomeWeb News) – DNA Electronics today announced a deal making its nucleic acid testing platform available to geneOnyx for cosmetic and skincare applications.
The commercial license and supply agreement provides geneOnyx access to DNA Electronics' Genalysis platform, which geneOnyx will use to analyze a person's genetic makeup to determine how that person will react to certain product ingredients.
Financial and other terms of the deal were not disclosed.
DNA Electronics said that the deal brings it into the non-in vitro diagnostic space. Pilot trials focused on the clinical diagnostics space for Genalysis are set to begin later this year.
Genalysis is a real-time, nucleic acid testing platform that delivers point-of-need results in about 30 minutes, using a sample processing kit and interchangeable test cartridges plugged into a USB stick or other electronic reader. Using a saliva sample from a mouth swab, purified, amplification-ready DNA is delivered to a complementary metal oxide semiconductor-based test cartridge, which amplifies and detects genetic signatures in the DNA.
Based in London, DNA Electronics develops electronic microchip-based tests for real-time nucleic acid detection. It has worldwide non-exclusive licensing deals with Roche's 454 Life Sciences and Life Technologies' Ion Torrent providing those firms access to parts of its technology for use in semiconductor sequencing.
geneOnyx provides cloud-based genetic analytics services and technology for cosmetic applications.